Santo Therapeutics raises tens of millions of yuan in Angel+ round to advance lentiviral gene therapy pipeline

Santo Therapeutics, a biotechnology company focused on advancing gene therapies, has completed an Angel+ financing round, raising tens of millions of Chinese Yuan. The round was exclusively invested by FIRHealth Capital. The proceeds will be used to advance the development of the company's globally leading lentiviral gene therapy pipeline.

Lentiviral vectors (LVs) are regarded as a preferred tool for next-generation gene therapy due to their advantages in packaging capacity, transfection efficiency, and long-term stable expression. Santo Therapeutics possesses extensive experience in the design and development of lentiviral vectors. Its latest generation of LV platform enables safe, effective, and cost-controllable in vivo gene therapy. The company has established collaborations with numerous top-tier research institutions and leading tertiary hospitals, boasting a pipeline of several candidates in the preclinical research stage. Among these, its neurofibromatosis program has the potential to become a first-in-class therapy globally in its treatment domain.

Santo Therapeutics stated: "FIRHealth Capital's professional insight and long-term commitment in the biotechnology sector give us full confidence in this collaboration. This investment not only represents strong recognition of Santo's leading advantages in the lentiviral vector field but also demonstrates a deep strategic alignment in the gene therapy industry. We are also deeply grateful to our existing shareholders for their ongoing support, as well as our medical partners and patients for their trust. This financing will support Santo in achieving key milestones, accelerating the China-US dual submissions for our drug pipeline and further advancing innovative research projects."

FIRHealth Capital stated: "We have consistently and firmly invested in innovative biotechnologies and therapies, including cell and gene therapies. The technical expertise and breakthroughs achieved by Santo Therapeutics in the field of lentiviral vector design are truly exciting. We look forward to working hand-in-hand with the company to pioneer a new era in gene therapy."

Santo Therapeutics was founded in November 2023 and is dedicated to developing in vivo gene therapies based on next-generation lentiviral vector recombinant technology. The team brings over 20 years of experience in vector optimization and disease mechanism research, with findings published multiple times in esteemed international journals. Leveraging three independently developed technology platforms, Santo is advancing breakthrough gene therapies targeting globally urgent medical needs. The company's vision is to achieve "one-time treatment, lifelong cure" through gene therapy, delivering long-term health improvements for patients.

FIRHealth Capital  was founded in 2021 and is the most promising new fund in the field of biomedical health. The company specializes in innovative investment and value discovery in the global biomedical industry. The team brings together high-level talents in the industry, scientific research and venture capital fields, and has Our team brings together high-caliber professionals from industry, academia, and venture capital, possessing extensive experience in both the pharmaceutical sector and investment.

As a dedicated player in the healthcare sector, FIRHealth Capital not only pursues the success and returns of its investments, but is also committed to advancing medical technology and benefiting human health. Joining hands with outstanding scientists and entrepreneurs, we aim to co-create a new chapter in life sciences.